卡托普利对冠心病患者内源性纤溶系统活性的影响

Captopril enhances the endogenous fibrinolytic system in of the coronary heart disease patients

目的探讨卡托普利对不稳定性心绞痛（ＵＡＰ）和急性心肌梗死（ＡＭＩ）患者内源性纤溶系统的影响及其临床意义。方法４０例ＡＭＩ和ＵＡＰ患者随机分为卡托普利组和对照组。采用发光底物显色方法，检测两组治疗前和治疗后第３、７、１４、２１天血浆组织型纤溶酶原激活剂（ｔＰＡ）及其抑制物（ＰＡＩ）的活性。结果治疗前血浆ｔＰＡ活性呈现正常人＞ＵＡＰ＞ＡＭＩ患者，ＰＡＩ活性则相反，而且ＡＭＩ与ＵＡＰ，ＵＡＰ和正常人同项比较均有显著性差异（Ｐ＜０．０１）。卡托普利组血浆ＰＡＩ活性降低，ｔＰＡ活性增强，与治疗前和对照组同期比较差异显著（Ｐ＜０．０５，０．０１）。结论卡托普利增强冠心病患者内源性纤溶系统活性。

Obijective The influence and clinical significance of catopril effect on endogenous fibrinolytic system activity in patients with acute myocardial infarction(AMI)and unstable angina pectoris(UAP) were in vestigated.Methods Activities of detected plasma tissus type plasminogen activator(tPA) and plasminogen activator inhibitor(PAI) were checked by chromogenic substrate in 40 UAP and AMI patients.Results Before treatment plasma tPA activity was significantly lower in patients with AMI and UAP than that of control group( P <0 05),and also lower in patients with AMI than UAP( P <0 05).In captopril group,plasma PAI activity were significantly lower and plasma PAI activity were significantly higher,than the control group and before treatment.Conclusion Captopril enhances the endogenous fibrinolytic system in patients with AMI and UAP.